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Abstract 
The	 clinical	 diagnosis	 of	 inherited	 renal	 tubulopathies	 can	 be	 challenging,	 as	 they	 are	 rare	
characterized	by	significant	phenotypic	variability.	Advances	in	sequencing	technologies	facilitate	the	
establishment	 of	 a	 molecular	 diagnosis.	 We	 aimed	 to	 investigate	 the	 diagnostic	 yield	 of	 a	 next	
generation	sequencing	panel	assessing	relevant	disease	genes	in	children	with	a	clinical	diagnosis	of	a	
renal	 tubulopathy	followed	through	three	national	networks.	DNA	was	amplified	with	a	kit	provided	
by	the	European	Consortium	for	High-Throughput	Research	in	Rare	Kidney	Diseases	with	9	multiplex	
PCR	reactions	producing	571	amplicons	to	cover	37	genes	associated	with	tubulopathies,	followed	by	
massively	parallel	sequencing	and	bioinformatic	 interpretation.	 Identified	mutations	were	confirmed	
by	Sanger	sequencing.	Overall,	we	assessed	384	index	patients	and	16	siblings.	Most	common	clinical	
diagnoses	were	Bartter/Gitelman	syndrome	(N=174)	and	distal	renal	tubular	acidosis	(N=76).	A	total	of	
269	 different	 variants	 were	 identified	 in	 27	 genes,	 of	 which	 95	 were	 considered	 likely	 and	 136	
definitely	pathogenic	and	100	had	not	been	described	at	annotation.		These	mutations	established	a	
genetic	diagnosis	in	245	(64%)	of	the	index	patients.	.	Genetic	testing	changed	the	clinical	diagnosis	in	
16	(4%)	of	cases	and	provided	insights	into	the	phenotypic	spectrum	of	the	respective	disorders.			
Our	results	demonstrate	a	high	diagnostic	yield	of	genetic	testing	in	children	with	a	clinical	diagnosis	
of	 a	 renal	 tubulopathy,	 consistent	 with	 a	 predominantly	 genetic	 etiology	 in	 known	 disease	 genes.	
Genetic	 testing	 helped	 establish	 a	 definitive	 diagnosis	 in	 almost	 two	 thirds	 of	 patients	 and	 thereby	
informed	prognosis,	management	and	genetic	counselling.	
	
Key	words:	Genetic	testing,	next	generation	sequencing,	tubulopathy,	children,	Bartter	syndrome,	
Gitelman	syndrome,	renal	tubular	acidosis	 	
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Introduction	
The	 renal	 tubules	 reabsorb	 the	vast	majority	of	 the	glomerular	 filtrate	and	 in	 this	way	preserve	 the	
“milieu	interieur”	and	maintain	homeostasis	critical	for	normal	physiology.1	This	task	is	performed	by	
an	 array	 of	 specialised	 transporters	 and	 channels,	 the	 dysfunction	 of	which	 can	 lead	 to	 number	 of	
specific	disorders,	 collectively	 referred	 to	as	 tubulopathies.	While	 tubulopathies	 can	be	 inherited	or	
acquired,	 identification	 of	 a	 genetic	 basis	 in	 inherited	 forms	 is	 desirable	 as	 it	 establishes	 a	 clear	
diagnosis,	 enabling	 specific	 work-up,	 genetic	 counselling	 and	 cascade	 screening	 of	 at-risk	 relatives.	
Moreover,	 clinical	 observations	 in	 genetically	 stratified	 cohorts	 of	 patients	 not	 only	 help	
understanding	of	 the	 role	of	 the	causal	 gene,	but	also	enable	 collection	of	 long-term	outcome	data	
that	 inform	prognosis	and	management	of	patients	affected	by	 the	 respective	disorder.2	Previously,	
individual	candidate	genes	based	on	clinical	suspicion	were	sequenced;	a	process	suitable	if	the	clinical	
diagnosis	is	convincing	and	only	a	single	gene	needs	to	be	screened.	However,	several	tubulopathies	
can	be	caused	by	multiple	genes	and/or	have	phenotypic	overlap	with	other	disorders,	such	as	Bartter	
and	Gitelman	syndromes	or	distal	renal	tubular	acidosis,	making	a	single	gene	approach	cumbersome	
and	 expensive.	With	 the	 advent	 of	 next	 generation	 sequencing	 (NGS),	 simultaneous	 sequencing	 of	
multiple	genes	has	become	 feasible	and	 is	 increasingly	performed.	Driven	by	 the	 rapidly	decreasing	
costs	 of	 NGS,	 whole	 exome	 or	 even	 whole	 genome	 sequencing	 is	 increasingly	 utilized,	 but	 panel	
sequencing	of	selected	genes	provides	the	advantage	of	achieving	high	coverage	of	genes	of	interest	
at	lower	cost.3	The	working	group	for	tubulopathies	in	the	European	Consortium	for	High-Throughput	
Research	in	Rare	Kidney	Diseases	(EURenOmics)4	designed	a	kit	for	targeted	amplification	of	37	known	
tubulopathy	disease	genes.	Here	we	describe	our	experience	with	this	kit	in	a	cohort	of	410	patients	
from	 384	 families,	 recruited	 predominantly	 from	 dedicated	 networks	 for	 renal	 tubulopathies	
centralized	in	London,	Paris	and	Brussels.			
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Results	
	
Gene	amplification	and	sequencing	
The	depth	and	horizontal	coverage	of	the	panel	were	assessed	after	the	first	run	(23	samples).		All	of	
the	 targeted	regions	were	covered	at	>	30X	except	 for	exon	one	of	OCRL	and	WNK1,	both	of	which	
have	 a	 high	GC	 content.	 These	 exons	were	 assessed	by	 Sanger	 sequencing	 in	 those	patients	with	 a	
clinical	diagnosis	compatible	with	one	of	these	genes	and	no	other	identified	causative	mutation.		
	
Patients	
A	total	of	384	index	patients	and	26	siblings	were	assessed.	The	most	common	clinical	diagnosis	was	
“Bartter/Gitelman	syndrome”	(N=174)	and	dRTA	(N=76),	followed	by	Pseudohypoaldosteronism	type	
1	 (PHA1,	 N=31)	 and	 Nephrogenic	 Diabetes	 Insipidus	 (NDI,	 N=23)	 and	 a	 genetic	 diagnosis	 could	 be	
established	in	74,	58,	42	and	83%,	respectively.	A	list	of	the	clinical	diagnoses,	the	respective	number	
of	patients	and	the	diagnostic	yield	is	provided	in	table	1.		
	
Genes	
A	 total	 of	 37	 known	 tubulopathy	 disease	 genes	 were	 assessed.	 The	 genes	 that	 most	 commonly	
provided	 a	 genetic	 diagnosis	 were	 SLC12A3	 (63	 patients),	 CLCNKB	 (29	 patients),	 SLC12A1	 and	
ATP6V0A4	(22	patients	each).	A	list	of	the	37	genes,	the	number	of	different	mutations	identified	and	
the	number	of	patients,	in	whom	they	provided	a	genetic	diagnosis	is	provided	in	table	2.	
	
Variants	
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A	 total	 of	 269	 different	 variants	were	 identified	 in	 27	 genes,	 of	which	 136	were	 deemed	 definitely	
(class	 5)	 and	 95	 likely	 pathogenic	 (class	 4),	 as	 well	 as	 36	 of	 unknown	 significance	 (class	 3).	 One	
hundred	variants	had	not	been	reported	previously	at	time	of	annotation.	The	class	4	and	5	mutations	
provided	 a	 likely	 or	 definite	 genetic	 explanation	 of	 the	 clinical	 phenotype	 in	 245	 (64%)	 of	 the	 384	
tested	 index	patients	and	 in	270	 (66%)	of	 the	overall	cohort.	23	 index	patients	had	affected	siblings	
and	the	 identified	mutation(s)	were	subsequently	also	found	in	the	siblings.	A	 list	of	all	patients	and	
their	 identified	 mutations	 is	 provided	 in	 supplemental	 table	 1,	 with	 reference	 sequences	 used	 for	
annotation	provided	 in	 supplemental	 table	2.	A	 list	of	 all	mutations	 identified	with	assigned	variant	
class,	arranged	by	gene	and	with	novel	mutations	highlighted	is	provided	in	supplemental	table	3.	The	
previously	 known	mutations	 (positive	 controls,	 see	 supplemental	 table	 4)	were	 all	 identified	 (100%	
sensitivity).	 All	 putative	 disease	 causing	 variants	 identified	 by	 the	 panel	 were	 confirmed	 by	 Sanger	
sequencing.	
	
	
	
Genetic	revision	of	the	clinical	diagnosis	
Genetic	results	lead	to	revision	of	the	clinical	diagnosis	in	22	(16	index)	patients	(see	table	3).	Ten	(4	
index)	 patients	with	 a	 clinical	 diagnosis	 of	 idiopathic	 hypercalciuria/nephrocalcinosis	were	 found	 to	
have	 either	 heterozygous	 (N=7)	 or	 bi-allelic	mutations	 (N=3)	 in	SLC34A3,	 establishing	 a	 diagnosis	 of	
hypophosphatemic	rickets	with	hypercalciuria	(HHRH)	or	 its	carrier	status.	 In	9	patients,	 the	revision	
was	from	Bartter	to	Gitelman	syndrome	(N=6)	or	vice	versa	(N=3,	all	with	mutations	in	CLCNKB).	One	
patient	with	a	clinical	diagnosis	of	“Dent	disease/rickets”	(P151)	and	one	with	“hypokalemia”	(P103)	
were	 found	to	have	distal	 renal	 tubular	acidosis	 (dRTA)	by	genetic	 testing.	Patient	L70	had	a	clinical	
diagnosis	of	Gitelman	syndrome,	yet	was	found	to	have	autosomal	dominant	tubulointerstitial	kidney	
disease	 (ADTKD),	 based	 on	 a	 heterozygous	 deletion	 of	HNF1B.	 A	 renal	 ultrasound	 at	 the	 age	 of	 14	
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years	was	 initially	 reported	 as	 normal,	 but	 on	 review	 showed	 increased	 echogenicity	with	 reduced	
corticomedullary	differentiation.	
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Discussion	
We	 report	 the	 use	 of	 targeted	 amplification	 and	 NGS	 of	 37	 “tubulopathy	 genes”	 in	 a	 large	
multinational	cohort	of	patients	with	childhood-onset	renal	tubulopathies.	Our	most	striking	finding	is	
the	 high	 diagnostic	 yield,	 which	 far	 surpasses	 the	 experience	 in	 other	 disease	 areas.	 In	 steroid-
resistant	nephrotic	syndrome,	the	reported	diagnostic	yield	varies	between	23-	30%,	although	it	is	far	
lower	for	patients	presenting	after	the	first	year	of	life.5,	6	In	nephronophthisis-related	ciliopathies	the	
reported	 yield	 is	 around	 20-25%,7,	 8	 while	 it	 is	 even	 lower,	 around	 5-15%,	 in	 CAKUT.9,	 10	 Our	 high	
diagnostic	 yield	 is	 comparable	 to	 previously	 reported	 cohorts	 of	 patients	 with	 autosomal	 recessive	
dRTA	 and	 Gitelman	 syndrome.11,	 12	 This	 is	 consistent	 with	 the	 concept	 that	 the	 vast	 majority	 of	
childhood-onset	 tubulopathies	 have	 a	 genetic	 basis	 and	 that	 the	majority	 of	 causative	 genes	 have	
been	 identified.	 Inclusion	 of	 more	 genes	 into	 the	 panel	 may	 have	 increased	 the	 yield	 further.	 For	
example,	 there	 were	 8	 index	 patients	 with	 a	 clinical	 diagnosis	 of	 infantile	 hypercalcemia,	 but	 no	
genetic	 diagnosis	 and	 one	 of	 the	 known	 causative	 genes,	CYP24A1,	 was	 not	 included	 in	 the	 panel.	
Similarly,	 neither	 PHEX	 nor	 FGF23	 were	 included	 to	 assess	 the	 patient	 with	 a	 clinical	 diagnosis	 of	
hypophosphatemic	 rickets,	who	had	no	underlying	mutation	 identified.	More	genes	associated	with	
hypomagnesemia	have	been	identified	since	the	development	of	the	panel,	 inclusion	of	which	might	
have	established	a	genetic	diagnosis	in	the	patients	with	a	clinical	diagnosis	of	hypomagnesemia	and	
thus	increased	the	diagnostic	yield.	The	absence	of	these	genes	demonstrates	the	limitations	of	such	a	
panel	 and	 the	 need	 for	 regular	 updates,	whilst	 striking	 a	 balance	 between	 the	 expected	 diagnostic	
yield	and	cost	efficiency.	
Interestingly,	we	noted	a	high	conformity	of	clinical	and	genetic	diagnosis	suggesting	that	an	accurate	
clinical	 diagnosis	 can	be	established	 in	most	 cases.	Renal	 tubulopathies	 are	 characterized	by	 typical	
constellations	of	clinical	and	biochemical	findings,	which	can	pinpoint	a	diagnosis.13-15	Although	there	
was	 discrepancy	 between	 the	 clinical	 and	 genetic	 diagnosis	 in	 22	 cases,	 the	 revision	 was	 rarely	
substantial.	 In	most	cases	 the	diagnosis	changed	 from	Bartter	 to	Gitelman	or	vice	versa.	Phenotypic	
overlap	 between	 Bartter	 type	 3	 and	 Gitelman	 syndromes	 is	 well	 recognized.16,	 17	 Of	 interest	 is	 the	
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change	 in	 diagnosis	 in	 patient	 L70	 from	 Gitelman	 syndrome	 to	 ADTKD.	 While	 electrolyte	
abnormalities,	 especially	 hypomagnesemia,	 but	 also	 hypokalemia	 have	 been	 previously	 associated	
with	HNF1B	mutations,	this	has	been	in	patients	with	concurrent	renal	malformations,	such	as	cystic	
dysplasia,	which	was	not	reported	as	present	in	the	ultrasound	from	this	patient.18,	19		
In	addition,	genetic	testing	established	a	specific	diagnosis	in	several	patients	with	a	clinical	diagnosis	
of	idiopathic	hypercalciuria/nephrocalcinosis,	mostly	on	the	basis	of	mutations	in	SLC34A3.	Recessive	
mutations	 in	 this	 gene	 cause	 HHRH	 and	 carriers	 have	 been	 described	 to	 have	 hypercalciuria.20	 The	
establishment	of	a	diagnosis	of	dRTA	in	the	2	patients	with	a	clinical	diagnosis	of	“hypokalemia”	and	
“Dent	disease/rickets”	likely	reflects	the	occasional	difficulties	in	establishing	a	diagnosis	of	dRTA	early	
in	life,	as	well	as	an	associated	proximal	tubulopathy,	which	we	reported	in	two-thirds	of	patients	with	
dRTA	 at	 initial	 presentation	 and	 appears	 to	 be	 linked	 to	 the	 acidosis.21	 Indeed,	 the	 features	 of	 the	
proximal	tubulopathy	disappeared	with	correction	of	the	acidosis	also	in	this	patient.	Overall,	the	high	
diagnostic	 yield	 and	 the	 lack	 of	 substantial	 revision	 of	 the	 diagnosis	 in	 the	 vast	 majority	 of	 cases	
suggests	a	high	level	of	clinical	expertise	present	in	the	respective	tubulopathy	networks.	
Yet,	 even	 in	 cases	 where	 the	 clinical	 diagnosis	 was	 confirmed,	 there	 was	 occasional	 diagnostic	
uncertainty,	 where	 genetic	 testing	 helped	 clarify	 the	 situation:	 for	 instance,	 there	 were	 2	 patients	
(patients	L103	and	L104),	who	initially	presented	to	their	local	hospital	in	the	first	month	of	life	with	
failure	 to	 thrive	 and	 were	 found	 to	 have	 hyponatremia,	 hyperkalemia	 and	 acidosis	 with	 elevated	
aldosterone	levels,	suggesting	a	clinical	diagnosis	of	PHA1.	However,	when	the	children	were	assessed	
in	 the	 tubulopathy	 clinic	 at	 3	 and	 5	months	 of	 life,	 respectively,	 no	 abnormalities	were	 found:	 the	
children	were	thriving	with	no	apparent	electrolyte	abnormalities,	normal	distal	potassium	secretion	
(transtubular	 potassium	 gradient,	 TTKG	 >	 8)	 and	 remained	 well	 also	 after	 weaning	 off	 the	 salt	
supplementation.	Consequently,	there	was	uncertainty	about	the	etiology	of	the	initial	presentation.	
There	was	no	family	history	of	PHA1	and	an	acquired	form	of	PHA1	was	considered,	for	instance	in	the	
context	of	a	urinary	tract	infection,	that	had	been	unrecognised	at	the	time	of	presentation	(both	had	
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initially	 received	 antibiotics	 due	 to	 their	 poor	 clinical	 state).22	 Yet,	 in	 both	 cases	 we	 identified	
heterozygous	mutations	 in	NR3C2,	 the	gene	encoding	 the	mineralocorticoid	 receptor,	establishing	a	
diagnosis	 of	 autosomal	 dominant	 PHA1.	 Spontaneous	 resolution	of	 symptoms	during	 childhood	has	
been	 reported	 in	 this	 disorder,	 as	 well	 a	 high	 proportion	 of	 asymptomatic	 adult	 NR3C2	 mutation	
carriers.23,	 24	Yet,	our	experience	here	suggests	that	symptoms	can	disappear	even	as	early	as	during	
the	 first	 few	months	 of	 life.	 Carriers	 of	 such	mutations	 nevertheless	 are	 reported	 to	 have	 lifelong	
increased	plasma	renin	and	aldosterone	levels.25		Consistent	with	this	observation,	aldosterone	levels	
in	our	patients	subsequently	returned	elevated	(L103:	5100,	L104:	2200,	normal	<700	pmol/l).	Apart	
from	providing	an	explanation	 for	 the	 initial	 severe	presentation,	 in	one	of	 these	 cases,	 the	genetic	
diagnosis	had	further	direct	clinical	 implications,	as	 it	allowed	early	diagnosis	 in	a	subsequently	born	
sibling.		
Other	 cases	 of	 diagnostic	 uncertainty	 were	 those	 of	 patients	 with	 complex	 phenotypes,	 i.e.	 with	
symptoms	beyond	the	tubulopathy.	For	instance,	the	pregnancy	with	patient	L19	was	complicated	by	
antenatally	 noted	 cardiac	 calcifications,	 as	 well	 as	 polyhydramnios.	 Postnatally,	 an	 annular	
calcification	at	the	root	of	the	aorta	was	seen,	as	well	as	nephrocalcinosis	and	she	was	noted	to	have	
hyperkalemia	 and	 hyponatremia,	 which	 over	 the	 first	 two	 weeks	 of	 life	 changed	 to	 the	 typical	
electrolyte	constellation	of	Bartter	syndrome	with	hypokalemic	alkalosis.	This	evolution	of	electrolyte	
abnormalities	was	consistent	with	a	diagnosis	of	Bartter	syndrome	type	2,	but	it	was	unclear	whether	
the	patient	suffered	from	an	unknown	complex	syndrome	that	included	a	Bartter-like	tubulopathy,	or	
whether	 there	 were	 two	 separate	 diagnoses:	 Bartter	 syndrome	 plus	 aortic	 calcification.	 Genetic	
testing	identified	a	homozygous	mutation	in	KCNJ1,	thus	suggesting	the	co-existence	of	two	separate	
diseases	in	this	offspring	of	a	consanguineous	marriage.	
An	 intriguing	 finding	 are	 the	 heterozygous	 mutations	 in	 ATP6V1B1	 c.1181G>A,	 p.(Arg394Gln)	 in	
patients	L80	and	L82	and	c.1180C>G,	p.(Arg394Gly)	in	patient	P73,	affecting	the	same	amino	acid.	The	
clinical	features	of	patient	L80	have	been	described	recently	and	like	those	of	L82	and	P73	clearly	fit	
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the	 phenotype	 of	 dRTA,21	 but	 with	 no	 evidence	 of	 hearing	 loss,	 a	 feature	 typical	 for	 patients	 with	
recessive	ATP6V1B1	mutations.	Given	that	ATP6V1B1	is	a	recessive	disease	gene,	the	dRTA	in	these	3	
patients	was	 defined	 as	 “genetically	 unsolved”.	 Yet,	 interestingly,	 this	mutation	has	 been	described	
previously	 in	only	heterozygous	 state	 in	patients	with	dRTA	with	 (mild)	or	without	hearing	 loss.12,	 26	
None	of	these	patients	have	a	recognized	family	history	of	dRTA,	arguing	against	a	dominant	negative	
effect,	unless	the	mutation	occurred	de	novo	 in	all.	We	were	only	able	to	test	the	parents	of	patient	
L80,	and	both	did	not	carry	this	variant,	arguing	for	a	de	novo	mutation.	The	variants	are	not	reported	
in	the	ExAC	browser	and	thus	likely	rare	and	present	in	these	patients	not	just	by	coincidence.	Further	
studies	are	needed	to	better	understand	a	potential	causality	of	this	variant.	
It	 is	 important	 to	 note	 that	 in	 this	 study	 only	 variants	 classified	 as	 “probably”	 or	 “definitely”	
pathogenic	 have	 been	 accepted	 as	 causative	 and	 used	 for	 the	 analysis.	 Yet,	 there	 were	 additional	
patients	 carrying	 variants	 of	 unknown	 significance	 (VUS),	 where	 a	 causative	 role	 is	 possible.	 For	
instance,	patient	L40	has	a	clinical	diagnosis	of	Bartter	 syndrome	type	4:	She	was	born	at	27	weeks	
gestation	 after	 a	 pregnancy	 complicated	 by	 polyhydramnios,	 noted	 to	 have	 hypochloremic,	
hypokalemic	 metabolic	 alkalosis	 and	 sensorineural	 deafness,	 treated	 with	 cochlear	 implants,	 all	
consistent	with	Bartter	 syndrome	 type	4.	Yet,	her	 subsequent	clinical	 course	was	unusually	mild	 for	
this	diagnosis.	She	has	grown	and	developed	normally	(at	the	age	of	16	years	now	on	the	25th	to	50th	
percentile	 for	height	and	weight),	attending	mainstream	schools	and	with	only	borderline	abnormal	
plasma	electrolytes.	Genetic	 testing	 in	her	 revealed	a	 recognized	pathogenic	mutation	 in	Barttin	on	
one	allele	(p.(Gly47Arg))	and	a	VUS	on	the	other	(p.(Ser42Asn)).	This	VUS	is	not	in	the	EXaC	database	
and	 thus	 unlikely	 a	 common	 polymorphism,	 but	 it	 scores	 low	 for	 pathogenicity	 in	 prediction	
algorithms	 (see	 supplemental	 table	1).	 It	 is	 tempting	 to	 speculate	 that	 the	 Ser42Asn	 variant	 retains	
some	Barttin	 functionality	 and,	 in	 trans	with	 the	Gly47Arg	 variant,	which	 itself	 has	 been	 associated	
with	a	less	severe	phenotype,	can	explain	the	unusually	mild	clinical	course.27	Overall,	there	were	25	
patients,	 in	 which	 we	 identified	 VUS	 in	 genes	 consistent	 with	 the	 clinical	 diagnosis	 and	 where	
pathogenicity	of	these	VUS	would	provide	a	genetic	explanation.	Thus,	it	is	likely,	that	the	true	genetic	
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identification	 rate	 is	 even	 higher	 than	we	 currently	 state.	 Identification	 of	 further	 patients	 carrying	
these	variants,	familial	segregation	analysis	and/or	functional	studies	may	change	the	classification	of	
these	variants	 in	 the	 future.	Moreover,	 a	potential	disadvantage	of	NGS	 is	 the	 limited	ability	 to	 call	
copy	number	variations	and	it	is	possible	that	we	may	have	missed	some	in	our	cohort.	Similarly,	the	
genetic	testing	in	this	cohort	was	performed	by	three	independent	clinical	genetic	laboratories	using	
their	own	respective	NGS	analysis	pipelines.	Different	platforms	can	yield	different	results	and	while	
there	 was	 no	 evidence	 for	 false	 positive	 findings,	 as	 all	 identified	 variants	 could	 be	 confirmed	 by	
Sanger	sequencing,	it	is	possible	that	individual	variants	may	have	been	missed.28	Again,	this	suggests	
that	the	true	number	of	patients	with	a	genetic	cause	in	a	recognized	disease	gene	is	even	higher	than	
we	state.	
	
An	interesting	finding	is	the	large	number	of	patients	with	a	genetic	diagnosis	of	Gitelman	syndrome	
(N=73),	accounting	for	almost	20%	of	the	entire	patient	cohort	and	similar	in	number	to	patients	with	
Bartter	syndrome	(N=72,	all	4	 tested	subtypes	combined)	and	substantially	more	 than	patients	with	
dRTA	(N=50,	all	3	tested	subtypes	combined).	Gitelman	syndrome	is	sometimes	considered	a	disorder	
mostly	presenting	 in	adulthood,	but	our	findings	clearly	argue	for	 its	relevance	 in	children,	as	well.16	
Our	 findings	 are	 consistent	 	 with	 the	 notion	 of	 Gitelman	 syndrome	 being	 the	 most	 common	
tubulopathy,	even	in	children.29		
In	contrast,	the	almost	complete	absence	of	patients	with	a	clinical	or	genetic	diagnosis	of	ADTKD	is	
surprising	and	may	represent	a	bias	in	our	cohort.	Whilst	mutations	in	MUC1	were	not	tested	for,	due	
to	the	technical	difficulties	of	 identifying	the	recognized	pathogenic	variant	by	NGS,	 this	mutation	 is	
very	rare.30	Patients	with	mutations	in	UMOD	may	predominantly	present	in	adulthood,	but	mutations	
in	 HNF1B	 have	 been	 recurrently	 reported	 in	 children	 with	 clinical	 signs	 of	 a	 tubulopathy.18,	 31	
Presumably,	the	usually	concurrent	renal	malformation	combined	with	the	relatively	easy	availability	
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of	 genetic	 testing	 for	HNF1B	 in	 the	 three	 involved	 countries	 has	 led	 to	 a	 lack	 of	 referring	 of	 such	
patients	to	the	laboratories,	as	most	already	had	a	genetic	diagnosis.	
Summary	
In	 conclusion,	 we	 find	 that	 comprehensive	 genetic	 testing	 of	 childhood-onset	 renal	 tubulopathies	
establishes	a	 likely	 genetic	diagnosis	 in	 the	majority32	of	patients	 referenced	 through	a	 tubulopathy	
network.	While	clinical	assessment	in	experienced	hands	can	accurately	identify	the	general	diagnosis	
in	most	cases,	 identification	of	the	molecular	basis	 is	still	needed	for	precise	genetic	counselling	and	
early	diagnosis	of	subsequent	siblings.	Genetic	testing	enables	dissection	of	complex	phenotypes	and	
patient	 stratification	 by	 genetic	 sub-diagnosis,	 such	 as	 the	 different	 types	 of	 Bartter	 syndrome	 and	
Gitelman	syndrome,	to	improve	our	understanding	of	the	associated	phenotype,	which	in	turn	informs	
patient	management.	The	early	resolution	of	clinical	symptoms	in	autosomal	dominant	PHA1	and	the	
Gitelman-like	 tubulopathy	without	 obvious	 renal	malformation	 associated	with	 an	HNF1B	mutation	
are	examples	for	such	insights	gained.	Moreover,	renal	tubulopathies	are	rare	kidney	diseases,	many	
of	which	nephrologists	practicing	outside	a	specialized	center	may	never	encounter	 in	their	 lifetime,	
leading	 to	 challenges	 in	 diagnosis	 and	 treatment.4	 Our	 study	 suggests	 that	 genetic	 testing	 is	 highly	
likely	 to	 help	 establish	 a	 specific	 diagnosis	 in	 children	with	 symptoms	 suggestive	 of	 a	 tubulopathy,	
allowing	targeted	management.	
	
Methods	
	
A	detailed	description	of	the	methods	is	provided	in	the	supplemental	appendix.	
Gene	selection	
In	2012,	the	tubulopathy	working	group	of	the	European	Consortium	for	High-Throughput	Research	in	
Rare	 Kidney	 Diseases	 (EURenOmics)	 met	 to	 decide	 on	 gene	 inclusion	 for	 a	 comprehensive	 genetic	
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testing	 panel.	 At	 the	 time,	 the	 group	 identified	 a	 total	 of	 37	 genes,	 mutations	 in	 which	 were	
recognized	 causes	of	 tubulopathies.	Only	 these	 and	no	 candidate	 genes	were	 included	 in	 the	panel	
(table	2).	
	
Patients	
DNA	 samples	 from	a	 total	 of	 410	patients	 from	384	 families	were	assessed.	 Included	were	patients	
with	a	clinical	diagnosis	of	a	tubulopathy	that	was	made	before	the	age	of	18	years	and	was	consistent	
with	 the	 37	 genes	 tested.	 Of	 these,	 139	 samples	 were	 analysed	 in	 London,	 195	 in	 Paris	 and	 76	 in	
Brussels.	Informed	consent	for	genetic	testing	was	obtained	by	the	respective	treating	physician	after	
approval	by	the	respective	institutional	review	boards,	in	accordance	with	the	Declaration	of	Helsinki.	
An	overview	of	the	clinical	diagnoses	is	provided	in	table	1.	A	list	of	all	patients	with	their	respective	
clinical	and	molecular	diagnosis	is	provided	in	supplemental	table	1.	Detailed	clinical	features	of	some	
patients	with	dRTA	and	Bartter	syndrome	have	been	reported	previously.21,	32-35	
	
Controls	
Samples	were	 tested	 from	22	 patients	with	 known	mutations	 in	 17	 different	 genes	 in	 the	 panel	 to	
determine	 the	 sensitivity	 of	 the	 assay.	 These	 “positive	 control”	 mutations	 included	 a	 spectrum	 of	
different	 types	 including	missense,	nonsense,	 splice	 site	and	whole	exon	deletions	present	 in	either	
homozygous,	heterozygous	and	hemizygous	state	and	are	listed	in	supplemental	table	4.	
	
Laboratory	
Genetic	testing	was	performed	in	three	clinical	genetic	laboratories:	
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1) The	North	East	 Thames	Regional	Genetics	 Services,	 located	at	GOSH,	which	 is	 accredited	 to	
ISO	 15189	 standard	 by	 the	 relevant	 UK	 authority	 (UKAS	 reference	 7883),	 allowing	 us	 to	
perform	genetic	testing	on	a	clinical	basis	with	provision	of	formal	reports.	
2) The	laboratory	of	molecular	genetics	of	the	HEGP	is	accredited	to	ISO	15189	standard	by	the	
relevant	French	authority	(COFRAC	reference	N°8-3147).	
3) The	laboratory	of	molecular	and	cellular	biology	at	the	IPG	institute,	which	is	accredited	to	ISO	
15189	standard	by	the	relevant	Belgian	authority	(BELAC	reference	381-MED).	
Gene	amplification	and	next	generation	sequencing		
The	 37	 target	 genes	 were	 amplified	 with	 a	 total	 of	 9	 multiplex	 PCR	 reactions	 generating	 571	
amplicons.	 MASTR	 kits	 for	 multiplex	 PCR	 were	 developed	 and	 provided	 by	 Multiplicom	
(www.multiplicom.com),	an	industry	partner	in	the	EURenOmics	consortium.	A	detailed	description	of	
the	NGS	library	generation	is	provided	in	the	supplementary	data.		
	
Bioinformatic	analysis	
Bioinformatic	analysis	was	performed	by	various	in	house	pipelines	in	the	three	laboratories	involved,	
detailed	 in	 the	 supplemental	methods.	 In	 general,	 variants	 had	 to	 be	present	 in	 20%	of	 at	 least	 30	
reads	to	be	called.		Further	filtering	excluded	variants	present	at	2%	or	greater	in	exome	variant	server	
(EVS)	or	1000	genomes	datasets	or	in	greater	than	four	patients	on	a	run	of	23	(unless	seen	in	patients	
with	 same	 clinical	 diagnosis).	 	 Samples	 were	 checked	 for	 copy	 number	 variations	 (CNV)	 using	 a	
combination	 of	 read	 depth	 (for	 homozygous	 deletions)	 and	 Exome	 Depth	 (http://cran.r-
project.org/web/packages/ExomeDepth/index.html).	 Alamut®Visual	 software	 (www.interactive-
biosoftware.com)	was	 used	 to	 assist	 in	 determining	 variant	 pathogenicity.	 The	 respective	 reference	
sequences	used	for	annotation	are	provided	in	supplemental	table	2.	
	 16	
Identified	 variants	 were	 checked	 against	 relevant	 databases,	 such	 as	 Clinvar	
(https://www.ncbi.nlm.nih.gov/clinvar/);	 HGMD	 (http://www.hgmd.cf.ac.uk/ac/index.php),	 Varsome	
(https://varsome.com/)	and	local	databases	to	assess	for	previous	publication.	
	
Variant	annotation	
Identified	 variants	 were	 annotated	 by	 the	 three	 involved	 clinical	 genetic	 laboratories	 according	 to	
published	 guidelines.36	 Variants	 were	 considered	 disease-causing,	 if	 they	 were	 consistent	 with	 the	
inheritance	pattern,	if	the	gene	in	which	they	were	identified	was	compatible	with	the	clinical	findings	
and	 if	 there	 was	 evidence,	 based	 on	 previous	 reports	 or	 prediction	 algorithms	 (SIFT,	 Align	 GVD,	
mutation	 taster	 and	 Polyphen2	 for	 pathogenicity,	 so	 that	 variants	 were	 either	 classified	 as	 “likely	
pathogenic”(class	4)	or	“definitely	pathogenic”	(class	5).	If	available,	segregation	was	assessed	within	
the	 family	 to	confirm	pathogenicity.	 “Variants	of	uncertain	significance”	 (class	3)	were	 recorded	but	
were	not	considered	disease-causing	for	the	purpose	of	this	study.	
Each	variant	identified	and	annotated	in	one	laboratory	was	independently	annotated	by	at	least	one	
of	 the	 other	 laboratories.	 For	 those	 variants	 with	 discordant	 annotation,	 final	 classification	 was	
reached	by	consensus	of	the	three	laboratories	using	the	relevant	guidelines.36	
	
Mutation	confirmation		
All	 identified	 mutations	 were	 confirmed	 by	 Sanger	 sequencing.	 Primers	 for	 mutation	 confirmation	
were	 designed	 using	 Primer	 3	 software	 (http://bioinfo.ut.ee/primer3).	 	 Sequencing	 was	 performed	
according	to	standard	methods	for	point	mutations.	
	
Disclosures	
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Table	legends	
Table	1:	Clinical	and	molecular	diagnosis	in	the	384	index	patients	
Shown	are	the	clinical	diagnoses,	respective	number	of	patients,	as	well	as	the	number	(proportion)	of	
patients	with	a	genetic	diagnosis.		
dRTA:	 distal	 renal	 tubular	 acidosis;	 pRTA:	 proximal	 renal	 tubular	 acidosis;	 PHA1:	
pseudohypoaldosteronism	type	1;	PHA2:	pseudohypoaldosteronism	type	2;	NDI:	nephrogenic	diabetes	
insipidus;	 FHH:	 familial	 hypercalcemic	 hypocalciuria;	 ADH:	 autosomal	 dominant	 hypercalcemia;	
FHHNC:	 familial	 hypomagnesemia	 with	 hypercalciuria	 and	 nephrocalcinosis;	 HOMG:	
hypomagnesemia;	HC/NC:	isolated	hypercalciuria/nephrocalcinosis	
	
Table	 2:	 The	 37	 genes	 included	 in	 the	 panel	with	 associated	 diagnosis,	 number	 of	 index	 patients	
with	causative	mutations	and	total	number	of	different	variants.	
Shown	is	a	list	of	the	37	genes	included	in	the	panel	and	the	number	of	index	patients	with	mutations	
in	 the	 respective	 genes.	 Variants	 were	 detected	 in	 26	 of	 the	 37	 genes	 tested.	 Note	 that	 the	 total	
number	of	variants	includes	those	of	uncertain	significance	and	thus	number	of	variants	may	exceed	
the	number	of	causative	mutations.	
ad:	 autosomal	 dominant;	 ar:	 autosomal	 recessive;	 Xl:	 X-linked;	 dRTA:	 distal	 renal	 tubular	 acidosis;	
pRTA:	 proximal	 renal	 tubular	 acidosis;	 PHA1:	 pseudohypoaldosteronism	 type	 1;	 PHA2:	
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pseudohypoaldosteronism	 type	 2;	 FHHNC:	 familial	 hypomagnesemia	 with	 hypercalciuria	 and	
nephrocalcinosis;	 HOMG:	 hypomagnesemia;	 NDI:	 nephrogenic	 diabetes	 insipidus;	 pRTA:	 proximal	
renal	 tubular	 acidosis;	 PHA2:	 pseudohypoaldosteronism	 type	 2,	 ADTKD:	 autosomal	 dominant	
tubulointerstitial	kidney	disease;	HHRH:	hereditary	hypophosphatemic	rickets	with	hypercalciuria	
	
3:	Index	patients	with	discrepant	clinical	and	genetic	diagnosis	
Listed	are	the	16	index	patients	in	whom	genetic	testing	changed	the	clinical	diagnosis,	as	well	as	their	
initial	clinical	and	subsequent	genetic	diagnosis.	
ADTKD:	 autosomal	 dominant	 tubulointerstitial	 kidney	 disease;	 dRTA:	 distal	 renal	 tubular	 acidosis;	
HHRH:	hereditary	hypophosphatemic	rickets	with	hypercalciuria		 	
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Table	1:	Clinical	and	genetic	diagnosis	in	the	384	index	patients	
Clinical	diagnosis	 Patients	(N)	 Genetic	diagnosis	N	(%)	
Bartter/	Gitelman	syndrome	 174	 128	(74)	
EAST	syndrome	 3	 2	(67)	
PHA1	 31	 13	(42)	
PHA2	 4	 3	(75)	
dRTA	 76	 44	(58)	
pRTA	 1	 1	(100)	
NDI	 23	 19	(83)	
FHH	 12	 5	(42)	
ADH	 1	 1	(100)	
Dent	disease	 15	 6	(40)	
Lowe	Syndrome	 1	 0	(0)	
FHHNC	 5	 4	(80)	
HOMG	 7	 4	(57)	
Infantile	hypercalcemia	 14	 6	(43)	
Hypophosphatemic	rickets	 5	 4	(80)	
HC/NC	 11	 4	(36)	
Hypokalemia	 1	 1	(100)	
Total	 385	 246	(70)	
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Table	2:	The	37	genes	included	in	the	panel	with	associated	diagnosis,	number	of	index	patients	
with	causative	mutations	and	total	number	of	different	variants.	
Gene Associated Diagnosis  MIM 
number 
Patients 
(N) 
Different variants 
(N) SLC12A1 Bartter syndrome type 1 601678 22 29 
 
 
KCNJ1 Bartter syndrome type 2 241200 9 9 
 
 
CLCNKB Bartter syndrome type 3 607364 29 21 
BSND Bartter syndrome type 4 602522 4 5 
 
SLC12A3 Gitelman syndrome  263800 63 70 
 
 
KCNJ10 EAST syndrome 612782 2 2 
NR3C2 PHA1, ad 177735 8 6 
SCNN1A 
 
PHA1, ar 264350 4 7 SCNN1B 
 
0 5 
SCNN1G 
 
1 1 
WNK1 
 
PHA2 
 
PHA2 
 
HOMG 
614492 0 
 
0 
0 
 
WNK4 614491 0 0 
CUL3 614496 0 
KLHL3 614495 3 3 
SLC4A1 
 
dRTA, ad and ar 
dRTA, ar 
 
179800 
267300 
602722 
6 
 
8 
ATP6V0A4 dRTA, ar 602722 22 24 
ATP6V1B1 18 
 
14 
SLC4A4 
 
pRTA with eye findings 
PHA2 
604278 1 2 
AQP2 NDI, ar 125800 2 4 
AVPR2 NDI, Xl 304800 17 13 
CaSR FHH 145980 5 
 
6 
GNA11 
 
145981 0 0 
AP2S1 600740 1 1 
CLCN5 Dent disease 1 300009 3 3 
OCRL Dent disease 2/Lowe syndrome 300555 3 5 
 
CLDN16 FHHNC 248250 4 5 
CLDN19 248190 0 2 
 
TRPM6  
HOMG 
 
602014 4 5 
EGF  611718 0 0 
FXYD2 145020 0 0 
KCNA1 176260 0 0 
HNF1B  
ADTKD 
 
137920 1 1 
REN  
 
613092 0 0 
UMOD 162000 0 0 
SLC34A1 Infantile Hypercalcemia 616963 4 7 
 
SLC34A3 HHRH 241530 9 11 
SLC9A3R1 Nephrolithiasias, 
hypophosphatemic 
Familial Hypercalcemia  
612287 0 0 
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Table	3:	Index	patients	with	discrepant	clinical	and	genetic	diagnosis	
Patient	 Clinical	diagnosis	 Genetic	diagnosis	
B39	 Gitelman	syndrome	 Bartter	syndrome	type	3	
L28	 Gitelman	syndrome	 Bartter	syndrome	type	3	
L38	 Gitelman	syndrome	 Bartter	syndrome	type	3	
B38	 Bartter	syndrome	 Gitelman	syndrome	
L54	 Bartter	syndrome	 Gitelman	syndrome	
P19	 Bartter	syndrome	 Gitelman	syndrome	
P20	 Bartter	syndrome	 Gitelman	syndrome	
P22	 Bartter	syndrome	 Gitelman	syndrome	
L44	 Bartter	syndrome	 Gitelman	syndrome	
L70	 Gitelman	syndrome	 ADTKD	HNF1B	
P151	 Dent	disease/rickets	 dRTA	
P103	 Hypokalemia	 dRTA	
P146	 Nephrocalcinosis	 HHRH	carrier	
P147	 Nephrocalcinosis	 HHRH	carrier	
P149	 Nephrocalcinosis	 HHRH	carrier	
P150	 Nephrocalcinosis	 HHRH	
	
	
